News Releases Keyword Search Year None20232022202120202019201820172016 Mar-10-2022 Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial Results Mar-07-2022 Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results Mar-01-2022 Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Jan-20-2022 Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies and Prostate Cancer Jan-04-2022 Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma Dec-13-2021 Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2021 Dec-01-2021 Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Nov-15-2021 Oncternal Therapeutics Presented Updated Interim Phase 1/2 Clinical Trial Data for ONCT-216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2021 Virtual Annual Meeting Nov-09-2021 Oncternal Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference Nov-04-2021 Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »